U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C18H25F3N4O.C4H4O4
Molecular Weight 486.4847
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 1
Charge 0

SHOW SMILES / InChI
Structure of ORG-13011 FUMARATE

SMILES

OC(=O)\C=C\C(O)=O.FC(F)(F)C1=CC(=NC=C1)N2CCN(CCCCN3CCCC3=O)CC2

InChI

InChIKey=KILJTUTVUORPFQ-WLHGVMLRSA-N
InChI=1S/C18H25F3N4O.C4H4O4/c19-18(20,21)15-5-6-22-16(14-15)24-12-10-23(11-13-24)7-1-2-8-25-9-3-4-17(25)26;5-3(6)1-2-4(7)8/h5-6,14H,1-4,7-13H2;1-2H,(H,5,6)(H,7,8)/b;2-1+

HIDE SMILES / InChI

Molecular Formula C18H25F3N4O
Molecular Weight 370.4125
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C4H4O4
Molecular Weight 116.0722
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 1
Optical Activity NONE

Approval Year

PubMed

PubMed

TitleDatePubMed
Practical application of cure mixture model for long-term censored survivor data from a withdrawal clinical trial of patients with major depressive disorder.
2010-04-23
Emotional reactivity and cognitive performance in aversively motivated tasks: a comparison between four rat strains.
2009-12-15
Olanzapine and fluoxetine combination therapy for treatment-resistant depression: review of efficacy, safety, and study design issues.
2009
Assessing the neuronal serotonergic target-based antidepressant stratagem: impact of in vivo interaction studies and knockout models.
2008-09
Gepirone extended-release in the treatment of adult outpatients with major depressive disorder: a double-blind, randomized, placebo-controlled, parallel-group study.
2008-04
Differential response to gepirone but not to chlordiazepoxide in malnourished rats subjected to learned helplessness.
2008-01
Acute and constitutive increases in central serotonin levels reduce social play behaviour in peri-adolescent rats.
2007-12
Early response and 8-week treatment outcome in GAD.
2006
The 5-HT1A receptor and the stimulus effects of LSD in the rat.
2005-10
Remission rates with 3 consecutive antidepressant trials: effectiveness for depressed outpatients.
2005-06
Novel, flexible, and conformationally defined analogs of gepirone: synthesis and 5-HT1A, 5-HT2A, and D2 receptor activity.
2005-02-15
Relapse prevention with gepirone ER in outpatients with major depression.
2005-02
[Review of antidepressants from the TCAs to the third generation drugs].
2004-12
Gepirone extended-release treatment of anxious depression: evidence from a retrospective subgroup analysis in patients with major depressive disorder.
2004-08
Cellular consequences of stress and depression.
2004-06
The design and preparation of metabolically protected new arylpiperazine 5-HT1A ligands.
2004-04-05
Use of physicochemical calculation of pKa and CLogP to predict phospholipidosis-inducing potential: a case study with structurally related piperazines.
2004-03
Metabolism of the newest antidepressants: comparisons with related predecessors.
2004-02
Differential effects of the 5-HT1A agonist gepirone on food intake in rats may depend on their motivation to eat.
2003-11
Pharmacokinetic evaluation of gepirone immediate-release capsules and gepirone extended-release tablets in healthy volunteers.
2003-09
A review of the efficacy and tolerability of immediate-release and extended-release formulations of gepirone.
2003-06
Sustained efficacy of gepirone-IR in major depressive disorder: a double-blind placebo substitution trial.
2003-04-19
Gepirone extended-release: new evidence for efficacy in the treatment of major depressive disorder.
2003-03
Human cytochromes mediating gepirone biotransformation at low substrate concentrations.
2003-03
Is there a role for 5-HT1A agonists in the treatment of depression?
2003-02-01
Influence of housing conditions on the effects of serotonergic drugs on feeding behavior in non-deprived rats.
2003
Rigid analogues of buspirone and gepirone, 5-HT1A receptors partial agonists.
2002-11
5-HT1A receptor-mediated regulation of mitogen-activated protein kinase phosphorylation in rat brain.
2002-10-04
The clinical pharmacology of depressive states.
2002-03
Gepirone. Organon.
2001-08
Effects of serotonergic compounds on aqueous humor dynamics in monkeys.
2001-08
5-HT1A receptor agonists buspirone and gepirone attenuate apomorphine-induced aggressive behaviour in adult male Wistar rats.
2000-12
Involvement of 5-hydroxytryptamine(1A) receptors in nicotine-induced tail tremor in rats.
2000-11-10
Prenatal exposure to cocaine: effects on aggression in Sprague-Dawley rats.
1994-05
Effects of 5-HT1A agonists and 5-HT2 antagonists on haloperidol-induced dyskinesias in squirrel monkeys: no evidence for reciprocal 5-HT-dopamine interaction.
1989
Strychnine seizure potentiation by azaspirodecanedione anxiolytics in rats.
1988-10-18
Patents
Substance Class Chemical
Created
by admin
on Mon Mar 31 23:09:38 GMT 2025
Edited
by admin
on Mon Mar 31 23:09:38 GMT 2025
Record UNII
O6W064NQ9M
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ORG-13011 FUMARATE
Common Name English
ORG-13011-FUMARATE
Preferred Name English
2-PYRROLIDINONE, 1-(4-(4-(4-(TRIFLUOROMETHYL)-2-PYRIDINYL)-1-PIPERAZINYL)BUTYL)-, (E)-2-BUTENEDIOATE (1:1)
Systematic Name English
2-PYRROLIDINONE, 1-(4-(4-(4-(TRIFLUOROMETHYL)-2-PYRIDINYL)-1-PIPERAZINYL)BUTYL)-, (2E)-2-BUTENEDIOATE (1:1)
Systematic Name English
Code System Code Type Description
CAS
142494-13-1
Created by admin on Mon Mar 31 23:09:38 GMT 2025 , Edited by admin on Mon Mar 31 23:09:38 GMT 2025
PRIMARY
PUBCHEM
70682615
Created by admin on Mon Mar 31 23:09:38 GMT 2025 , Edited by admin on Mon Mar 31 23:09:38 GMT 2025
PRIMARY
FDA UNII
O6W064NQ9M
Created by admin on Mon Mar 31 23:09:38 GMT 2025 , Edited by admin on Mon Mar 31 23:09:38 GMT 2025
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY